Breakthrough in cancer immunotherapy shows promise in early trials
New immunotherapy approaches helped shrink tumors in early-stage patients across multiple cancer types. Researchers report improved response rates compared with standard care alone. Larger confirmatory trials and FDA review pathways are expected over the next several years.